Manreet Kaur, MD
Gastroenterology · Scottsdale, AZNPI 1134330236
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,322 of the $72,250 with a category attached, or 73.8%. 11 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 38.3% of the total. Reporting peaked in 2019 at $52,665 and has fallen 99.9% since, to $57 in 2025. Among gastroenterology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $347.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$28K
- AbbVie$22K
- Pfizer$14K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Gilead$2K
- Johnson & Johnson$2K
- plus $325 from 5 others
Across 249 payments — averaging $9651.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.2M
- Janssen Research & Development, LLC$642K
- Takeda Pharmaceuticals U.S.A., Inc.$313K
- Gilead$176K
- UCB Biosciences Inc.$44K
- F. Hoffmann-la Roche AG$33K
- plus $40K from 3 others
What the payments were for
- Consulting fees$8,18011%
- Speaking & faculty fees$53,32274%
- Travel & lodging$6,2799%
- Food & beverage$4,4346%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 29 | $27,645 |
| AbbVie | 86 | $21,875 |
| Pfizer | 13 | $14,435 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $4,016 |
| Gilead | 1 | $2,030 |
| Johnson & Johnson | 44 | $1,924 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $218 |
| Conmed Corporation | 1 | $59 |
| Redhill Biopharma Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,250 in reported general payments places this provider in the 95th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 15 | $4,571 |
| Balsalazide Disodium | 14 | $3,199 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Scottsdale
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
- Woong KimScottsdale$138K
- Adam HarrisScottsdale$127K
- Anil SeetharamScottsdale$111K
- Amar ThosaniScottsdale$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.